Literature DB >> 25488878

Changes in liver and spleen volumes after living liver donation: a report from the Adult-to-Adult Living Donor Liver Transplantation Cohort Study (A2ALL).

Jean C Emond1, Robert A Fisher, Gregory Everson, Benjamin Samstein, James J Pomposelli, Binsheng Zhao, Sarah Forney, Kim M Olthoff, Talia B Baker, Brenda W Gillespie, Robert M Merion.   

Abstract

Previous reports have drawn attention to persistently decreased platelet counts among liver donors. We hypothesized an etiologic association between altered platelet counts and postdonation splenomegaly and sought to explore this relationship. This study analyzed de-identified computed tomography/magnetic resonance scans of 388 donors from 9 Adult-to-Adult Living Donor Liver Transplantation Cohort Study centers read at a central computational image analysis laboratory. Resulting liver and spleen volumes were correlated with time-matched clinical laboratory values. Predonation liver volumes varied 2-fold in healthy subjects, even when they were normalized by the body surface area (BSA; range = 522-1887 cc/m(2) , n = 346). At month 3 (M3), postdonation liver volumes were, on average, 79% of predonation volumes [interquartile range (IQR) = 73%-86%, n = 165] and approached 88% at year 1 (Y1; IQR = 80%-93%, n = 75). The mean spleen volume before donation was 245 cc (n = 346). Spleen volumes greater than 100% of the predonation volume occurred in 92% of donors at M3 (n = 165) and in 88% at Y1 after donation (n = 75). We sought to develop a standard spleen volume (SSV) model to predict normal spleen volumes in donors before donation and found that decreased platelet counts, a younger age, a higher predonation liver volume, higher hemoglobin levels, and a higher BSA predicted a larger spleen volume (n = 344, R(2)  = 0.52). When this was applied to postdonation values, some large volumes were underpredicted by the SSV model. Models developed on the basis of the reduced sample of postdonation volumes yielded smaller underpredictions. These findings confirm previous observations of thrombocytopenia being associated with splenomegaly after donation. The results of the SSV model suggest that the biology of this phenomenon is complex. This merits further long-term mechanistic studies of liver donors with an investigation of the role of other factors such as thrombopoietin and exposure to viral infections to better understand the evolution of the spleen volume after liver donation.
© 2014 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25488878      PMCID: PMC4308432          DOI: 10.1002/lt.24062

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  26 in total

1.  Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver?

Authors:  M Peck-Radosavljevic; J Zacherl; Y G Meng; J Pidlich; E Lipinski; F Längle; R Steininger; F Mühlbacher; A Gangl
Journal:  J Hepatol       Date:  1997-07       Impact factor: 25.083

2.  Computed tomography versus magnetic resonance imaging--aided volumetry of the left lateral segment before living related liver donation: a case report.

Authors:  G Krupski; X Rogiers; V Nicolas; R Maas; M Malagó; C E Broelsch; E Bücheler
Journal:  Liver Transpl Surg       Date:  1996-09

Review 3.  The role of the liver in the production of thrombopoietin compared with erythropoietin.

Authors:  W Jelkmann
Journal:  Eur J Gastroenterol Hepatol       Date:  2001-07       Impact factor: 2.566

4.  Outcomes of 385 adult-to-adult living donor liver transplant recipients: a report from the A2ALL Consortium.

Authors:  Kim M Olthoff; Robert M Merion; Rafik M Ghobrial; Michael M Abecassis; Jeffrey H Fair; Robert A Fisher; Chris E Freise; Igal Kam; Timothy L Pruett; James E Everhart; Tempie E Hulbert-Shearon; Brenda W Gillespie; Jean C Emond
Journal:  Ann Surg       Date:  2005-09       Impact factor: 12.969

5.  Graft size assessment by preoperative computed tomography in living related partial liver transplantation.

Authors:  H Higashiyama; T Yamaguchi; K Mori; Y Nakano; T Yokoyama; T Takeuchi; N Yamamoto; Y Yamaoka; K Tanaka; K Kumada
Journal:  Br J Surg       Date:  1993-04       Impact factor: 6.939

6.  Palpable spleens: ten-year follow-up.

Authors:  F G Ebaugh; O R McIntyre
Journal:  Ann Intern Med       Date:  1979-01       Impact factor: 25.391

7.  Living donor liver transplantation: summary of a conference at The National Institutes of Health.

Authors:  Mitchell L Shiffman; Robert S Brown; Kim M Olthoff; Gregory Everson; Charles Miller; Mark Siegler; Jay H Hoofnagle
Journal:  Liver Transpl       Date:  2002-02       Impact factor: 5.799

8.  One-year morbidity after donor right hepatectomy.

Authors:  Dianne Lapointe Rudow; Robert S Brown; Jean C Emond; Douglas Marratta; Sarah Bellemare; Milan Kinkhabwala
Journal:  Liver Transpl       Date:  2004-11       Impact factor: 5.799

9.  Liver regeneration and surgical outcome in donors of right-lobe liver grafts.

Authors:  Elizabeth A Pomfret; James J Pomposelli; Fredric D Gordon; Nazli Erbay; Lori Lyn Price; W David Lewis; Roger L Jenkins
Journal:  Transplantation       Date:  2003-07-15       Impact factor: 4.939

10.  Adult-adult living donor liver transplantation.

Authors:  Masatoshi Makuuchi; Charles M Miller; Kim Olthoff; Myron Schwartz
Journal:  J Gastrointest Surg       Date:  2004 Mar-Apr       Impact factor: 3.452

View more
  2 in total

1.  Defining long-term outcomes with living donor liver transplantation in North America.

Authors:  Kim M Olthoff; Abigail R Smith; Michael Abecassis; Talia Baker; Jean C Emond; Carl L Berg; Charlotte A Beil; James R Burton; Robert A Fisher; Chris E Freise; Brenda W Gillespie; David R Grant; Abhinav Humar; Igal Kam; Robert M Merion; Elizabeth A Pomfret; Benjamin Samstein; Abraham Shaked
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

Review 2.  Living donor liver transplantation in the USA.

Authors:  Peter T W Kim; Giuliano Testa
Journal:  Hepatobiliary Surg Nutr       Date:  2016-04       Impact factor: 7.293

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.